Search
Raymond James Biotech Innovation Symposium: Wave Life Sciences CEO Paul Bolno discusses the recent INHBE data and previews alpha-1 antitrypsin deficiency data being presented next month
He discusses the INHBE data and the market reaction to it, which he believes is due to misconceptions about the patient population, and the next steps for this program. Plus, an AATD presentation that will happen next month at American Thoracic Society. Coverage brought to you by
Apr 14
SF Healthcare Week: Wave Life Sciences CEO Paul Bolno discusses the company's INHBE obesity program, AATD, PNPLA3, and more
He describes the 'best-in-class' profile he believes INHBE can show in the obesity space. Plus the latest on other programs and how Wave is working on a new a new bifunctional modality.
Jan 14
Jones Healthcare & Technology Innovation Conference: Wave CEO Paul Bolno discusses recent DMD data and regulatory feedback, and shares updates on alpha-1 antitrypsin, obesity, and Huntington's
He describes the 48 week data for the exon 53 DMD program, and discusses the company's plan to seek accelerated approval. Plus, guidance...
Apr 9, 2025
Wave Life Sciences' CEO Paul Bolno discusses Phase 1b/2a data from the company's allele-selective Huntington's program
Paul Bolno highlights biomarker and safety data in Huntington's, the potential regulatory path ahead, and what to watch throughout the rest
Jun 26, 2024
Wave Life Sciences demonstrates high throughput oligonucleotide synthesis and talks RNA editing
Paul Bolno shows us how Wave discovers and develops its own oligonucleotides as Wave prepares to enter the clinic with RNA editing.
Aug 4, 2023
.png){kind=logo}
